Neurocrine Biosciences, Inc. (NBIX)
128.41
-3.03
(-2.31%)
USD |
NASDAQ |
Apr 16, 16:00
128.42
+0.01
(+0.01%)
After-Hours: 20:00
Neurocrine Biosciences Cash from Investing (Quarterly) : -52.90M for Dec. 31, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Soleno Therapeutics, Inc. | -125.36M |
| Glaukos Corp. | -15.89M |
| Edgewise Therapeutics, Inc. | 49.76M |
| Nuvalent, Inc. | -280.94M |
| Biogen, Inc. | -1.232B |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 388.40M |
| Cash from Financing (Quarterly) | 37.30M |
| Free Cash Flow | 748.70M |
| Free Cash Flow Per Share (Quarterly) | 3.769 |
| Free Cash Flow to Equity (Quarterly) | 399.20M |
| Free Cash Flow to Firm (Quarterly) | 390.80M |
| Free Cash Flow Yield | 5.69% |